Academic Journals Database
Disseminating quality controlled scientific knowledge

One year on glatiramer acetate. Preliminary report on disease activity and disability evolution

Author(s): Vitalie Văcăraş | Zoltán Z. Major | Anca D. Buzoianu

Journal: Human & Veterinary Medicine
ISSN 2066-7655

Volume: 4;
Issue: 3;
Start page: 107;
Date: 2012;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: Glatiramer acetate | relapse | EDSS | multiple sclerosis

Glatiramer acetate for relapsing-remitting multiple sclerosis has already a long history, even if the drug still lacks a precise mechanismof action, and the performed research raised some controversies. Still, the overall clinical effect of the drug is generally thought as beneficial.Our goal was to apply a combined battery of clinical assessment methods, to evaluate the impact of chronic glatiramer acetate treatmenton disease activity and disability evolution. This preliminary report shows a beneficial effect of the drug on the relapse rate and on the score ofthe Expanded Disability Status Scale after one year of continuous treatment, versus non-treated subjects.
RPA Switzerland

Robotic Process Automation Switzerland


Tango Rapperswil
Tango Rapperswil